Vimarsana
Biggest News Aggregation in the World

Iodixanol Injection News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Iodixanol Injection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Iodixanol Injection Today - Breaking & Trending Today

Fresenius Kabi Further Expands Radiology Portfolio with Launch of Gadobutrol Injection - Vimarsana News

Fresenius Kabi Further Expands Radiology Portfolio with Launch of Gadobutrol Injection

FDA-approved generic for MRI procedures is fully substitutable for Gadavist 

Fresenius Kabi Expands Contrast Agent Portfolio with Launch of Gadoterate Meglumine Injection, USP - Vimarsana News

Fresenius Kabi Expands Contrast Agent Portfolio with Launch of Gadoterate Meglumine Injection, USP

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Oct 4, 2022--

Source: wsiltv.com
Fresenius Kabi Launches Generic Iodinated Contrast Media Agent to Alleviate Shortage - Vimarsana News

Fresenius Kabi Launches Generic Iodinated Contrast Media Agent to Alleviate Shortage

Fresenius Kabi announced the launch of Iodixanol Injection, a generic equivalent to Visipaque.

Source: empr.com
Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion - Vimarsana News

Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion

Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion Contribution of Sales of New Products to Revenue Rises to 47.4% Driving Revenue Up by 16.4% HONG KONG, May 24, 2021 - (ACN Newswire) - Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited first quarterly results for the three months ended 31 March 2021. Development Highlights -- Chia Tai - Tianqin...